• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Cefiderocol Demonstrates Potent In Vitro Activity Against Multidrug-Resistant Gram-Negative Uropathogens

by
November 14, 2026
in Health
Reading Time: 5 mins read
0
Cefiderocol Demonstrates Potent In Vitro Activity Against Multidrug-Resistant Gram-Negative Uropathogens

Cefiderocol Demonstrates Potent In Vitro Activity Against Multidrug-Resistant Gram-Negative Uropathogens

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In an in vitro evaluation of 110 clinical Gram-negative bacterial isolates recovered from hospitalized patients with urinary tract infections, researchers observed widespread multidrug resistance and substantial resistance to the newer therapeutic combination ceftazidime-avibactam, while the novel siderophore cephalosporin cefiderocol demonstrated potent and consistent antimicrobial activity across nearly all tested pathogens. Published in the Future Journal of Pharmaceutical Sciences, the investigation analyzed clinical uropathogens consisting of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa that were previously collected from routine diagnostics at Mansoura University Hospitals in Egypt and cataloged in the laboratory collection at Zagazig University. Across the complete sample cohort, 80.9 percent of the bacterial isolates fulfilled the criteria for multidrug resistance, displaying widespread non-susceptibility to multiple standard antibiotic classes, including broad-spectrum beta-lactams, fluoroquinolones, and aminoglycosides. Resistance to ceftazidime-avibactam occurred in 51.8 percent of the overall collection, driven predominantly by high failure rates among Klebsiella pneumoniae and Pseudomonas aeruginosa, whereas cefiderocol retained high inhibitory activity even against isolates producing metallo-beta-lactamases and carbapenemases.

Urinary tract infections represent one of the most widespread bacterial diseases globally, with an estimated worldwide annual burden reaching approximately 150 million cases across varied demographic groups and inpatient clinical environments. Depending on the anatomical location of bacterial colonization and tissue invasion, these infections manifest clinically as cystitis in the urinary bladder, pyelonephritis in the kidneys, or urethritis in the lower urinary tract.

To evaluate potential therapeutic options against these formidable bacterial pathogens, the investigators examined a well-defined experimental collection of 110 non-duplicate urinary isolates, comprising 47 strains of Escherichia coli, 30 strains of Klebsiella pneumoniae, 22 strains of Pseudomonas aeruginosa, and 11 strains of Proteus mirabilis. The bacterial strains had been recovered during routine diagnostic microbiological testing from patients diagnosed with urinary tract infections admitted to several specialized centers across Mansoura University Hospitals in Egypt. Following their transfer from preserved stocks maintained at minus 80 degrees Celsius in tryptone soya broth supplemented with 20 percent glycerol at Zagazig University, every clinical isolate underwent systematic phenotypic re-identification. Confirmation protocols involved standardized Gram staining, colony morphology assessment on selective MacConkey agar plates, growth screening on cetrimide agar specifically targeting Pseudomonas aeruginosa, and an array of standard biochemical assays. These biochemical validations included triple sugar iron agar reactions, indole production, citrate utilization, motility, oxidase activity, and urease production to establish definite taxonomic identities prior to comprehensive antimicrobial resistance profiling.

Antimicrobial susceptibility profiling was conducted using Kirby-Bauer disk diffusion methods according to standard Clinical and Laboratory Standards Institute guidelines, supplemented by European Committee on Antimicrobial Susceptibility Testing criteria for tigecycline interpretations. The laboratory panel evaluated nineteen distinct therapeutic agents representing eight major antimicrobial classes: amoxicillin, amoxicillin-clavulanic acid, piperacillin, piperacillin-tazobactam, cefotaxime, ceftazidime, cefepime, ceftazidime-avibactam, cefiderocol, imipenem, meropenem, meropenem-vaborbactam, aztreonam, tigecycline, trimethoprim-sulfamethoxazole, gentamicin, tobramycin, amikacin, and levofloxacin. Multidrug resistance was documented in 89 of the 110 isolates, reflecting an overall cohort prevalence of 80.9 percent. Proteus mirabilis exhibited the highest multidrug resistance rate at 100 percent, followed closely by Pseudomonas aeruginosa at 91 percent and Klebsiella pneumoniae at 90 percent. Conversely, Escherichia coli exhibited a multidrug resistance rate of 66 percent. Pairwise statistical analysis using Fisher exact tests confirmed that the multidrug resistance burden in Escherichia coli was significantly lower than that recorded for Proteus mirabilis with a p-value of 0.025, Klebsiella pneumoniae with a p-value of 0.028, and Pseudomonas aeruginosa with a p-value of 0.039.

Detailed examination of specific antibiotic classes revealed pervasive resistance patterns across conventional treatment options. Escherichia coli isolates demonstrated extensive resistance against amoxicillin-clavulanic acid at 89.4 percent, alongside 66 percent non-susceptibility to both ceftazidime and aztreonam, though resistance remained lower against amikacin and meropenem-vaborbactam at 25.5 percent each. Klebsiella pneumoniae isolates showed complete 100 percent resistance to amoxicillin and amoxicillin-clavulanic acid, with resistance exceeding 90 percent for ceftazidime, cefotaxime, cefepime, and aztreonam. Proteus mirabilis strains similarly exhibited 100 percent resistance to amoxicillin-clavulanic acid, 91 percent resistance to cefotaxime, and 81.8 percent resistance to cefepime; all Proteus mirabilis isolates were non-susceptible to tigecycline, which the authors affirmed represents predictable intrinsic resistance rather than acquired non-susceptibility. Pseudomonas aeruginosa isolates exhibited marked non-susceptibility, reaching 95.5 percent resistance against ceftazidime and cefepime, with resistance to other tested antimicrobial classes averaging 91 percent.

The experimental performance of ceftazidime-avibactam revealed pronounced species-dependent divergence when measured across both disk diffusion assays and confirmatory resazurin-based broth microdilution tests. Across the tested cohort, minimum inhibitory concentration values for ceftazidime-avibactam spanned a wide range from 2 to 1024 micrograms per milliliter. Proteus mirabilis isolates remained entirely susceptible, showing 100 percent susceptibility across both testing formats. Escherichia coli also retained substantial sensitivity, with 68.1 percent susceptibility indicated by disk diffusion and 70.2 percent susceptibility confirmed via broth microdilution. In sharp contrast, ceftazidime-avibactam resistance was extensive among Klebsiella pneumoniae isolates, where 83.3 percent proved resistant, and among Pseudomonas aeruginosa isolates, which demonstrated 77.3 percent resistance on disk diffusion and 81.8 percent resistance during microdilution testing, highlighting substantial therapeutic failure risks.

In stark contrast to the extensive resistance observed with ceftazidime-avibactam, cefiderocol displayed remarkable in vitro potency against the evaluated uropathogens, including strains carrying extensive resistance profiles. Disk diffusion measurements revealed that cefiderocol remained active against virtually all tested Gram-negative isolates, recording an exceptionally low resistance rate of only 3.3 percent in Klebsiella pneumoniae and maintaining zero resistance among Proteus mirabilis strains.

To elucidate the molecular and phenotypic drivers underpinning these antimicrobial resistance profiles, the authors selected 55 multidrug-resistant isolates with the highest overall resistance phenotypes for detailed beta-lactamase characterization. Phenotypic screening for extended-spectrum beta-lactamase production via modified double-disk synergy testing revealed positive results in 100 percent of tested Proteus mirabilis isolates, 86.7 percent of Klebsiella pneumoniae, 80 percent of Escherichia coli, and 33.3 percent of Pseudomonas aeruginosa strains. Phenotypic carbapenemase production, evaluated through the modified carbapenem inactivation method, was identified in 86.7 percent of Klebsiella pneumoniae, 73.3 percent of Pseudomonas aeruginosa, and 55 percent of Escherichia coli isolates. Metallo-beta-lactamase synthesis, determined using EDTA-modified carbapenem inactivation and imipenem-EDTA combined disk tests, closely paralleled overall carbapenemase production, appearing in 86.7 percent of Klebsiella pneumoniae, 73.3 percent of Pseudomonas aeruginosa, and 50 percent of Escherichia coli strains. In contrast, all examined Proteus mirabilis isolates tested entirely negative across all phenotypic carbapenemase and metallo-beta-lactamase detection assays, corroborating their retained susceptibility to carbapenem agents.

Genotypic evaluation by conventional polymerase chain reaction revealed an extensive distribution of beta-lactamase resistance genes among the 55 selected multidrug-resistant isolates, providing a direct molecular explanation for the observed ceftazidime-avibactam resistance. Among Escherichia coli strains, the most common genes detected were the class A enzyme blaTEM at 85 percent and the metallo-beta-lactamase blaNDM-1 at 75 percent, with blaSHV detected in 35 percent and both blaVIM-1 and blaOXA-48 identified in 25 percent of isolates. In Klebsiella pneumoniae, blaNDM-1 predominated at 86.7 percent, alongside blaOXA-48 at 66.7 percent, blaVIM-1 at 64.7 percent, blaSHV at 53.3 percent, and blaTEM at 33.3 percent. Pseudomonas aeruginosa exhibited a diverse repertoire dominated by blaNDM-1 at 60 percent, blaGES at 53.3 percent, blaVIM-A at 53.3 percent, blaOXA-48 at 46.7 percent, and blaIMP-B at 26.7 percent. Proteus mirabilis isolates harbored only blaTEM at 100 percent and blaSHV at 40 percent, lacking any carbapenemase or metallo-beta-lactamase genes. Across all tested bacterial isolates, the class A carbapenemase gene blaKPC was completely absent.

Furthermore, because avibactam cannot inhibit class B metallo-beta-lactamases, the high prevalence of circulating blaNDM-1 and blaVIM genes directly explains the high rates of ceftazidime-avibactam failure. The authors concluded that the proliferation of metallo-beta-lactamases poses an urgent challenge in hospital environments, necessitating rigorous surveillance programs and strict antimicrobial stewardship to prevent unnecessary selective pressure and preserve the clinical utility of reserve therapies like cefiderocol.

Subject of Research: In vitro antimicrobial susceptibility of multidrug-resistant Gram-negative uropathogens to ceftazidime-avibactam and cefiderocol

Article Title: In vitro efficacy of ceftazidime/avibactam and cefiderocol against multidrug-resistant Gram-negative uropathogens: insights into β-lactamase-mediated resistance in clinical isolates

Article References: Ibrahim, M. A., Abbas, H. A., Shaker, G. H., & El-Baz, A. M. (2026). In vitro efficacy of ceftazidime/avibactam and cefiderocol against multidrug-resistant Gram-negative uropathogens: insights into β-lactamase-mediated resistance in clinical isolates. Future Journal of Pharmaceutical Sciences, 12(1), Article 48. https://doi.org/10.1186/s43094-026-00946-3

Image Credits: AI Generated

DOI: 10.1186/s43094-026-00946-3

Keywords: ceftazidime-avibactam, cefiderocol, urinary tract infections, uropathogens, multidrug resistance, Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, metallo-beta-lactamases, carbapenemases, extended-spectrum beta-lactamases, blaNDM-1, blaOXA-48, blaVIM-1, disk diffusion testing, broth microdilution, siderophore cephalosporins

News Source: Ophelia Keating. (November 14, 2026). Cefiderocol Demonstrates Potent In Vitro Activity Against Multidrug-Resistant Gram-Negative Uropathogens. Scienmag.

Tags: blaNDM-1blaOXA-48blaVIM-1broth microdilutioncarbapenemasescefiderocolceftazidime-avibactamdisk diffusion testingEscherichia coliExtended spectrum beta-lactamasesKlebsiella pneumoniaemetallo-beta-lactamasesmultidrug resistanceProteus mirabilisPseudomonas aeruginosasiderophore cephalosporinsurinary tract infectionsUropathogens
Share12Tweet7Share2ShareShareShare1

Related Posts

Kashmir Hospital Study Profiles Workload and Seasonal Patterns in Minor Surgery

Kashmir Hospital Study Profiles Workload and Seasonal Patterns in Minor Surgery

November 20, 2026
Exercise Prescriptions and Nearby Facilities Increase Stated Willingness in China

Exercise Prescriptions and Nearby Facilities Increase Stated Willingness in China

November 20, 2026

Early Serum Uric Acid Decline Links to Survival After Cardiac Arrest

November 20, 2026

Gephyrin Interactions and Receptor Competition Drive Structural Diversity Across Inhibitory Synapses

November 20, 2026

POPULAR NEWS

  • Review Evaluates Integrins as Potential Mediators and Targets in Metabolic Disorders

    Review Evaluates Integrins as Potential Mediators and Targets in Metabolic Disorders

    29 shares
    Share 12 Tweet 7
  • Tutorial Review Synthesizes Evolution and Applications of Remote Sensing Multimodal Models

    29 shares
    Share 12 Tweet 7
  • Blood MicroRNA Level Predicts Late Cytomegalovirus Infection in High-Risk Kidney Recipients

    29 shares
    Share 12 Tweet 7
  • Insurance Deductions Impact Up to Half of Hospital Records in Iranian Study

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Kashmir Hospital Study Profiles Workload and Seasonal Patterns in Minor Surgery

Exercise Prescriptions and Nearby Facilities Increase Stated Willingness in China

Review Assesses NINJ1 Oligomerization and Membrane Rupture in Regulated Cell Death

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.